Biochemistry of multidrug resistance mediated by the multidrug transporter

MM Gottesman, I Pastan - Annual review of biochemistry, 1993 - annualreviews.org
This year there will be approximately 1,000,000 new cases of cancer in the United States.
Close to half of these are still localized at the original site when the patient comes to the …

Nanomedicinal strategies to treat multidrug-resistant tumors: current progress

X Dong, RJ Mumper - Nanomedicine, 2010 - Future Medicine
Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. P-
glycoprotein is an important and the best-known membrane transporter involved in MDR …

Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct …

CP Leith, KJ Kopecky, J Godwin… - Blood, The Journal …, 1997 - ashpublications.org
Compared with younger patients, elderly patients with acute myeloid leukemia (AML)
respond poorly to conventional chemotherapy. To determine if this poor response is due to …

Drug resistance: still a daunting challenge to the successful treatment of AML

BC Shaffer, JP Gillet, C Patel, MR Baer, SE Bates… - Drug Resistance …, 2012 - Elsevier
Resistance to chemotherapy remains a challenging issue for patients and their physicians. P-
glycoprotein (Pgp, MDR1, ABCB1), as well as a family of structurally and functionally related …

Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells

M Bebawy, V Combes, E Lee, R Jaiswal, J Gong… - Leukemia, 2009 - nature.com
Multidrug resistance (MDR), a significant impediment to the successful treatment of cancer
clinically, has been attributed to the overexpression of P-glycoprotein (P-gp), a plasma …

Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A …

CP Leith, KJ Kopecky, IM Chen… - Blood, The Journal …, 1999 - ashpublications.org
Therapeutic resistance is a major obstacle in the treatment of acute myeloid leukemia (AML).
Such resistance has been associated with rapid drug efflux mediated by the multidrug …

Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation

RZ Yusuf, Z Duan, DE Lamendola… - Current cancer drug …, 2003 - ingentaconnect.com
It has been approximately ten years since the Food and Drug Administration (FDA)
approved paclitaxel for the treatment of platinum resistant epithelial ovarian carcinoma …

Multidrug resistance: molecular mechanisms and clinical relevance

V Ling - Cancer chemotherapy and pharmacology, 1997 - Springer
Multidrug resistance (MDR) describes the phenomenon of simultaneous resistance to
unrelated drugs. It has been a decade since the P-glycoprotein (Pgp) gene, which is …

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

AF List, KJ Kopecky, CL Willman… - Blood, The Journal …, 2001 - ashpublications.org
Abstract Cyclosporine A (CsA) inhibits P-glycoprotein (Pgp)–mediated cellular export of
anthracyclines at clinically achievable concentrations. This randomized controlled trial was …

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer

A Mayer, M Takimoto, E Fritz, G Schellander, K Kofler… - Cancer, 1993 - Wiley Online Library
Background. Proliferating cell nuclear antigen (PCNA), a proliferation marker, epidermal
growth factor receptor (EGFR), a glycoprotein that plays a role in tumorigenesis by binding …